The Supreme People’s Court has upheld administrative penalties imposed on Huang Chemical concerning findings of price-fixing and market allocation arrangements in the camphor active pharmaceutical ingredient sector. The decision reinforces the application of China’s anti-monopoly framework to conduct involving horizontal coordination among competitors. Such practices are recognized as capable of distorting market pricing mechanisms and undermining fair competition within upstream pharmaceutical supply chains.
The ruling further highlights the regulatory scrutiny applied to anti-competitive conduct that may adversely affect downstream pharmaceutical manufacturers and end consumers. It also reflects the judiciary’s continued emphasis on maintaining orderly market competition and safeguarding consumer welfare. In this context, foreign investors and market entrants in China’s pharmaceutical sector are advised to ensure robust compliance with applicable competition law and regulatory requirements.